Overview

NoNO’s therapeutic products stem from fundamental academic research conducted by two of its founding scientists, Dr. Michael Tymianski and Dr. Michael Salter. These products focus largely on molecular targets with the central nervous system (CNS), and have well-characterized mechanisms of action. The company has identified three important therapeutic targets to which it has developed corresponding products:

  • NA-1, a proprietary molecule which targets PSD-95 proteins found in neuronal synapses
  • Antagonists of TRPM7 ion channels antagonists and inhibitors of Src-ND2 interactions.

The Company’s lead therapeutic, NA-1, has been developed successfully through completed Phase 1 and Phase 2 trials in the United States and Canada.

The Company is now conducting a global Phase 3 trial (ESCAPE NA-1/NA-1-007) to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with a major Acute Ischemic Stroke as well as a second trial in Canada (FRONTIER/NA-1-005) in patients with acute cerebral ischemia.

Management

Michael Tymianski CM, MD, PhD, FRCSC, FAHA

President and CEO

Dr. Tymianski founded NoNO Inc. in 2003 to commercialize development technology stemming from his research laboratory. Dr. Tymianski holds the current positions of Head of the Division of Neurosurgery at the University Health Network in Toronto and Medical Director of the Neurovascular Therapeutics Program. He is a Staff Neurosurgeon at the Toronto Western Hospital and Senior Scientist at the Krembil Research Institute. He is a Professor in the Departments of Surgery and Physiology at the University of Toronto. He is the Harold and Esther Halpern Chair in Neurosurgical Stroke Research and a Canada Research Chair (Tier 1) in Translational Stroke Research. In his research laboratory, he studies the cellular and molecular mechanisms that cause brain cells to die during a stroke, and new drug treatments for protecting the brain from being damaged by stroke and other injuries. Dr. Tymianski was appointed as a member of the Order of Canada in December 2016.

Michael W. Salter MD, PhD

Vice President, Finance

Dr. Salter is the co-founder of NoNO Inc. In addition, Dr. Salter is the Chief of Research at The Hospital for Sick Children Research Institute, holds the Northbridge Chair in Pediatric Research. He is also a Professor of Physiology at the University of Toronto and is the former Director of the University of Toronto Centre for the Study of Pain. In 2005 he was elected as a fellow of the Royal Society of Canada, and in 2006 he received the Distinguished Career Award from the Canadian Pain Society. Dr. Salter is one of Ontario’s leading pain researchers. His research focuses on the genetic, cellular and molecular signalling processes leading to chronic pain in humans.
The goal is a new generation of drugs that can target and treat chronic pain and, in some instances, even repair damaged nerves.

Dave Garman PhD

Chief Technology Officer

Dr. Garman joined NoNO Inc in 2010 to expand the company’s capabilities in preclinical development, clinical development and manufacturing. Dr. Garman has over 30 years of experience in laboratory science and has spent the past 18 years in biotechnology, holding various positions encompassing scientific management, quality, manufacturing, intellectual property and business development functions. He brings a strong background in biochemistry, assay development, clinical manufacturing, quality, intellectual property and preclinical development. This includes more than 13 years in the development of neurotherapeutics. Dr. Garman received his PhD in Developmental Biology from Stanford University.

Kathy Heard MSc

Director Clinical Development

Kathy has more than 15 years of clinical research experience in various areas including vaccines, atopic dermatitis and stroke. Kathy is currently responsible for the oversight of clinical trials pertaining to NoNO’s clinical programs. She has experience in all stages of clinical development and her area of expertise includes global project and regulatory management. Prior to NoNO Inc., she was the Director of Study Management and Logistics at Sanofi Pasteur heading up the Asia Pacific team from Singapore and prior to that the Canadian team from Toronto. She has also worked in project management with a large multinational clinical research organization. Kathy holds a Master’s in Science in Pharmaceutical Medicine and is an adjunct lecturer in clinical research at the Karolinska Institute and Hibernia College.

Sibel Ok MSc

Director, Regulatory Affairs

Sibel has about 17 years of experience in the pharmaceutical industry, specifically in global product development and regulatory strategies. She also has experience in filing and registration of new drug applications, developing relationships with regulatory authorities and achieving priority review and approval for new chemical entities. Prior to NoNO, Inc., Sibel has worked at global pharmaceutical companies in registration and commercial launch of pharmaceutical and biological products, as well as various global filing for ANDA/S.
She holds a Master’s of Science in Synthetic Organic Chemistry, has extensive knowledge in chemistry and manufacturing controls (CMCs), and is certified in project management and communication for Business professionals.

Michal Helbin MSc Pharm

Director Quality Assurance and Training

Michal has more than 20 years of pharmaceutical industry experience.
Prior to joining NoNO Inc. as a Director Quality Assurance and Training in 2016, Michal worked for government and private companies. After graduation from Medical Academy in 1995, Michal worked as an Inspector at the Ministry of Health. Working at Bristol-Myers Squibb Co. Michal obtained his clinical operations experience conducting 2 large cardiovascular studies in Central and Eastern Europe, Russia and Turkey. In 2003 Michal was promoted to Global Quality Manager and was responsible for PV, Bioethics and Good Clinical Practice. In 2007 Michal was hired by ApoPharma Inc. a division of Apotex Inc. and was responsible for implementation of quality systems.
Michal holds a Master’s Degree in Pharmacy from the Medical University of Warsaw, Poland

Board of Directors

Michael Tymianski CM, MD, PhD, FRCSC, FAHA

Dr. Michael Tymianski is the President and CEO of NoNO Inc., which he founded in 2003. Dr. Tymianski holds the current positions of Medical Director of the Neurovascular Therapeutics Program and Head of the Division of Neurosurgery at the University Health Network in Toronto. He is a Staff Neurosurgeon at the Toronto Western Hospital and Senior Scientist at the Toronto Western Hospital Research Institute. He is a Professor in the Departments of Surgery and Physiology at the University of Toronto and he teaches and supervises medical students, residents and clinical fellows. In his research laboratory, he studies the cellular and molecular mechanisms that cause brain cells to die during a stroke, and new drug treatments for protecting the brain from being damaged by stroke and other injuries. Dr. Tymianski was appointed as a member of the Order of Canada in December 2016.

Michael W. Salter MD, PhD

Dr. Salter is the co-founder of NoNO Inc. In addition, Dr. Salter is the Chief of Research at The Hospital for Sick Children Research Institute, holds the Northbridge Chair in Pediatric Research. He is also a Professor of Physiology at the University of Toronto and is the former Director of the University of Toronto Centre for the Study of Pain. In 2005 he was elected as a fellow of the Royal Society of Canada, and in 2006 he received the Distinguished Career Award from the Canadian Pain Society. Dr. Salter is one of Ontario’s leading pain researchers. His research focuses on the genetic, cellular and molecular signalling processes leading to chronic pain in humans.
The goal is a new generation of drugs that can target and treat chronic pain and, in some instances, even repair damaged nerves.

Mark Krembil

Mr. Krembil is the President of the Krembil Foundation, a family foundation that supports medical research and child education. Previously, he was co-owner of Lewiscraft, a national Canadian retail company, and he has held a senior position in System Engineering at EDS Canada. Mr. Krembil is a graduate of the University of Toronto and currently serves as the Vice Chair of the Ontario Neurotrauma Foundation, and is on the board of directors for Earth Rangers, NeuroScience Canada and NoNO Inc.

Greg Wolfond

Mr. Wolfond is the founder and CEO of Blue Sky Capital, a private investment company, and the Chairman and CEO of SecureKey Technologies Inc., a digital security company. Mr. Wolfond founded Footprint Software Inc., a financial software company, and later sold the company to IBM. Additionally, he founded and was CEO of 724 Solutions Inc., a wireless software infrastructure provider which he took public in 2000. Mr. Wolfond holds the 1994 award for Canada’s Best Managed Private Company for Footprint Software, and the 1995 award for Canada’s top 40 under 40. In 2000, he was awarded the Entrepreneur of the Year. In addition to his work with NoNO, Mr. Wolfond also sits on the boards of the Ontario Cancer Biomarker Network, and YYZ Pharmatech.

Josh Josephson OD, FAAO, FBCLA

Dr. Josephson is the CEO of Josephson Opticians Limited and serves as the Chairman of the Ophthalmic Devices Subcommittee of the Standards Council of Canada (TC 172/SC7). He has actively been involved in developing international standards for contact lenses, quality control and related products for nearly 30 years. Dr. Josephson has had an extensive research career, with over 95 publications in the ophthalmic area. He has served on the scientific advisory boards of several companies including Bausch and Lomb Inc. and 3M Vision Care and consulted for other organizations including International Hydron, Allergan Ophthalmics, Menicon Company and the U.S. military. In addition to his scientific accomplishments, Dr. Josephson is the proprietor of The Cookbook Store in Toronto.

John A.K. Francis

John Francis is the Managing Director of Fraser Kearney Capital Corp., an investment company that oversees the Francis family office. Prior to forming Fraser Kearney, John was President and CEO of Trader Media Corporation for 16 years where he grew revenues to $150 million from under $10 million. John serves on the advisory boards of Summerhill Venture Partners and Altas Partners. He chairs the boards of ScribbleLive, Inc., and National Salt Company Inc., portfolio companies of Summerhill and Altas respectively. He is also Chair of the Investment Committee for Rideau Hall Foundation. He is a director of The Toronto Foundation, OTI Lumionics and NoNo Inc. In addition, he is a director and past Chair of SickKids Foundation. John was educated at the Western University’s Ivey School of Business (Honours Business Administration, with Distinction, 1986) and serves on their Advisory Board.

Martin Goldfarb LL.D., O.C.

Martin Goldfarb is an entrepreneur and a leading expert in the study of human behavior as it relates to the marketplace and society. He is a Principal at Goldfarb Intelligence Marketing. He has consulted for Ford Motor Company, Toyota Europe and Manheim (Automotive Auctions), DeBeers, Four Seasons Hotels and Resorts, Speedy Muffler King, the Government of Canada, Scotiabank, and Trenitalia in Italy. He is currently Chairman, President and CEO of The Goldfarb Corporation, a TSX and then a NEX Board of the TSX Venture Exchange company, until it became a private corporation in 2011. Martin was a key adviser and strategist to the Right Honourable Pierre E. Trudeau. He is the author of several important books on marketing. In 1998 he was designated an Officer of the Order of Canada in recognition of his pioneering work in the market research industry and philanthropic activities.

Board Observers

Thomas O’Driscoll – Securities Attorney

Jay Lefton – Partner, Borden Ladner Gervais

Scientific Advisory Board

Michael W. Salter MD, PhD

Dr. Salter is the Head of the Program in Neurosciences and Mental Health and holds the Canada Research Chair in Neuroplasticity and Pain at the Hospital for Sick Children in Toronto. He is also a Professor of Physiology at the University of Toronto and Director of the University of Toronto Centre for the Study of Pain. In 2005 he was elected as a fellow of the Royal Society of Canada, and in 2006 he received the Distinguished Career Award from the Canadian Pain Society. Dr. Salter is one of Ontario’s leading pain researchers. His research focuses on the genetic, cellular and molecular signalling processes leading to chronic pain in humans. The goal is a new generation of drugs that can target and treat chronic pain and, in some instances, even repair damaged nerves.

Yu-Tian Wang MD, PhD

Dr. Wang is a professor in the Department of Medicine and the Brain Research Centre at the University of British Columbia (UBC). He also holds the Heart and Stroke Foundation of British Columbia and Yukon Chair in Stroke Research at the UBC and Vancouver Hospital and Health Sciences Centre. In 2006, he was elected to the Academy of Sciences of the Royal Society of Canada. Dr. Wang conducts investigations into the molecular mechanisms underlying AMPA receptor trafficking and synaptic plasticity.

James W. Gurd PhD

Dr. Gurd is Professor Emeritus of Biochemistry, University of Toronto. His research has focused on the central nervous system, including the effects of stress on the structure and function of synapses, and the effects of ischemia and seizure activity on synaptic proteins, including NMDA and AMPA receptors.

R. Andrew Tasker PhD, FCHAS

Dr. Tasker is a Professor of Neuropharmacology and Jeanne and J.Louis Levesque Research Professor at the University of Prince Edward Island. His research specialties include behavioral and molecular neuroscience; the pharmacology and toxicology of neurodegenerative diseases; the development and characterization of animal models of progressive neurological dysfunction; and the development of new therapeutics for use in stroke.

Michael Hill BSc, MSc, MD, FRCPC

Dr. Hill is a Professor for the Departments of Clinical Neurosciences, Community Health Sciences, Medicine and Radiology at the University of Calgary and Director of the Stroke Unit for the Calgary Stroke Program, Alberta Health Services. Dr. Hill completed medical school at the University of Ottawa his neurology residency at the University of Toronto and a stroke fellowship and clinical epidemiology training at the University of Calgary where he was appointed to faculty in 2001. Dr. Hill’s research interests include stroke thrombolysis, stroke epidemiology, surveillance and clinical trials.

Careers


Current Opportunities


Position:                 Vice President, Business Development – Pharmaceutical Sciences

Reports to:             Chief Executive Officer

Status:                     Permanent

Posted:                    March 24, 2017


Position:                 QA Project Leader

Reports to:             Director, Quality Assurance and Training

Status:                     Permanent

Posted:                    May 10, 2017


Position:                 Director of Biostatistics

Reports to:             Chief Executive Officer

Status:                     Permanent

Posted:                    May 10, 2017


Position:                 Regulatory Affairs Project Lead

Reports to:             Director, Regulatory Affairs

Status:                     Permanent

Posted:                    May 15, 2017